Novel oxysterols activate the Hedgehog pathway and induce osteogenesis

Frank Stappenbeck, Wei Xiao, Matt Epperson, Mariko Riley, Aaron Priest, Danwen Huang, KhanhLinh Nguyen, Michael E. Jung, R. Scott Thies, Francine Farouz

Department of Chemistry and Biochemistry, University of California, 607 Charles E. Young Drive East, Los Angeles, CA 90095, USA
Fate Therapeutics, 3535 General Atomics Court, Suite 200, San Diego, CA 92121, USA
Department of Chemistry and Biochemistry, University of California, 607 Charles E. Young Drive East, Los Angeles, CA 90095, USA

Abstract

Localized induction of bone formation is essential during orthopedic procedures that involve skeletal repair, such as surgical treatment of non-union bone fractures and degenerative disk disease. Herein, we disclose the synthesis and biological evaluation of novel oxysterol derivatives designed as anabolic bone growth agents. Structure–activity relationship studies of oxysterol 4 have identified analogues such as (18), (21) and (30). These new analogues are characterized by higher potency in an osteoblast differentiation assay and/or by increased metabolic stability in human liver microsomes. Oxysterol 4, (18) and (21) were evaluated in vivo in a rat spinal fusion model.

Keywords: Oxysterols, Bone formation, Structure–activity relationship, Hedgehog signaling, Spinal fusion, Deuterium incorporation.

Oxysterols are defined as oxygenated metabolites of cholesterol. Low concentrations of oxysterols occur naturally in the mammalian blood circulation and various tissues, commonly as short lived intermediates implicated in important metabolic transformations of cholesterol such as the biosynthesis of steroid hormones and bile acids. Beyond their role as passive metabolites, oxysterols can function as signaling molecules capable of modulating a range of physiological phenomena, among them transport mechanisms by which animal cells maintain the proper levels of intracellular lipids and cholesterol. Oxysterols have also been cited to play a role in the pathogenesis of human diseases (for example, atherosclerosis, Alzheimer’s disease, and diabetes mellitus) and their occurrence and distribution in the body may be characteristically altered by age and disease.

To account for their wide ranging biological effects, oxysterols bind complementary protein targets that often serve as physiological sensors. For example, liver X receptors (LXRx and β) and sterol regulatory element binding proteins (SREBPs) are involved in the mechanisms by which animal cells maintain the proper levels of intracellular lipids and cholesterol. Numerous reports have noted a role for oxysterols as mediators of cellular differentiation, such as the differentiation of multipotent mesenchymal stem cells (MSCs). Specific oxysterols such as 22-(R)-hydroxycholesterol can induce the differentiation of MSCs into cells expressing the osteoblast markers, alkaline phosphatase and osteocalcin, while inhibiting their differentiation into adipocytes. This process was shown to be mediated by the Hedgehog (Hh)-pathway, a signaling pathway linked to bone metabolism not only during embryonic development but also in postnatal maintenance of bone integrity and function. Decreased anabolic mineralization of adult bone tissue can lead to osteoporosis and impaired healing during skeletal injury, both serious health issues affecting elderly populations. Small molecule agonists of Hh-signaling may therefore be useful therapeutic agents in orthopedic medicine.

Localized induction of bone formation is of critical importance in orthopedic procedures that involve skeletal repair, for example, during surgical intervention in non-union bone fractures and degenerative disk disease. Various applications and devices containing bone morphogenetic protein (BMP-2 or BMP-7) have demonstrated clinical efficacies comparable to autogenous bone grafts; however, adverse events have raised safety concerns regarding the widespread use of expensive, recombinant BMP protein. Thus motivated in the quest for small molecule osteoinductive substances that are safe and cost effective, we have studied the use of naturally occurring oxysterols, 22-(R)-hydroxycholesterol (1), (S)-hydroxycholesterol (2), and (S)-hydroxycholesterol (3), depicted in Scheme 1, as potential osteogenic agents.

An inflection point was reached in our studies when a more potent oxysterol analog was identified with lead compound 4, which differs from 20-(S)-hydroxycholesterol (2) in the additional α-hydroxyl group at C-6 (Scheme 1). Compound 4, to the best of our knowledge, is not a naturally occurring oxysterol, unlike 1–3.
and its chemical synthesis was first reported by Djerassi et al., in 1973.\textsuperscript{17} During biological characterization, we have shown 4 to be efficacious as a single agent both in vitro and in vivo. In M2-10 B4 marrow stromal cells, compound 4 activated the Hh-pathway and induced the expression of both early osteoblast markers, alkaline phosphatase, runx2, osterix, and markers of more mature osteoblasts, bone sialoprotein and osteocalcin. In addition, compound 4 induced robust new bone formation when dosed in an in vivo model of rat spinal fusion.\textsuperscript{16} In this paper, we wish to discuss the synthesis and biological evaluation of additional analogues in this new class of synthetic oxysterols which can activate the Hh-pathway and induce the osteoblastic differentiation in a multipotent mouse cell line, C3H/10T1/2. In our efforts to develop structure activity relationships for 4, we have investigated side-chain modifications in the C20, 22 region of the molecule with the aim to identify molecules with greater in vitro activity as well as improved local metabolic stability. Compound 4 displays a side-chain constellation where the C-20 hydroxyl group is flanked by a methyl-group and an isohexyl-group in the S-configuration. By varying the nature, size and stereochemistry of the appropriate substituents, we sought to understand the resulting consequences of these variations with respect to activation of the Hh-pathway, measured by upregulation of the mediating transcription factor, Gli, in a SHHLight2 reporter cell line.\textsuperscript{18} The ability of test compounds to stimulate osteogenesis was measured in vitro using a murine C3H/10T1/2 cell line, tracking the transcriptional upregulation of several key markers, but especially the mature osteoblast marker, osteocalcin (OCN)\textsuperscript{19} 10 days into the differentiation process (Table 1). As our synthetic route readily allowed for variation of the large substituent (R', Table 1), we turned our attention first to the isohexyl side-chain. In accordance with Djerassi's original report,\textsuperscript{17} we found that compound 4 and its congeners can be prepared starting from commercially available pregnenolone (5a). The synthetic sequence involves protection of the C-3 hydroxyl group, addition of a Grignard reagent, followed by hydroboration/oxidation of the C-5,6 olefin and suitable deprotection. The diastereoselectivity of nucleophilic addition to pregnenolone (5a) is governed by the sterol substrate, so that the major products of Grignard additions to the C-20 carbonyl of 5b correspond to tertiary alcohols in the desired 20(S)-configuration, as predicted by the Felkin-Anh model.\textsuperscript{20} Alternatively, alkynyl lithium species can be added to 5b in excellent yield and diastereoselectivity. A synthesis for compound 4 is shown in Scheme 2, which was applied to most other analogues shown in Table 1, which summarizes the results.

![Scheme 1. Potential oxysterol osteogenic agents.](image1)

**Table 1**

<table>
<thead>
<tr>
<th>Compd</th>
<th>R'</th>
<th>R''</th>
<th>Hh light</th>
<th>OCN fold</th>
<th>HLM stab. %</th>
<th>left at 1 h</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>IsoHx</td>
<td>Me</td>
<td>0.8</td>
<td>15</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>21</td>
<td>n-Hx</td>
<td>Me</td>
<td>0.4</td>
<td>36</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>22</td>
<td>n-Heptyl</td>
<td>Me</td>
<td>0.5</td>
<td>17</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>23</td>
<td>n-Pentyl</td>
<td>Me</td>
<td>6.6</td>
<td>4</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>24</td>
<td>(CH\textsubscript{2})\textsubscript{4}Ph</td>
<td>Me</td>
<td>2.5</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>25</td>
<td>(CH\textsubscript{2})\textsubscript{3}3-Pyridyl</td>
<td>Me</td>
<td>1.2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>26</td>
<td>(CH\textsubscript{2})\textsubscript{4}4-Pyridyl</td>
<td>Me</td>
<td>&gt;5</td>
<td>3</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>27</td>
<td>n-Hx</td>
<td>Et</td>
<td>2.9</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>28</td>
<td>n-Hx</td>
<td>Ph</td>
<td>&gt;10</td>
<td>69</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>12</td>
<td>Me</td>
<td>IsoHx</td>
<td>&gt;10</td>
<td>69</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>29</td>
<td>(CH\textsubscript{2})\textsubscript{3}OMe</td>
<td>Me</td>
<td>3.1</td>
<td>3</td>
<td>35</td>
<td>1</td>
</tr>
<tr>
<td>18</td>
<td>(CD\textsubscript{2})\textsubscript{2}CH\textsubscript{2}CH(CH\textsubscript{2})\textsubscript{3}Me</td>
<td>Me</td>
<td>0.8</td>
<td>17</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>30</td>
<td>(CD\textsubscript{2})\textsubscript{2}(CH\textsubscript{2})\textsubscript{3}CH\textsubscript{2}Me</td>
<td>Me</td>
<td>0.3</td>
<td>35</td>
<td>100</td>
<td>100</td>
</tr>
</tbody>
</table>

\textsuperscript{a} Average values (n \geq 2).

\textsuperscript{b} Measured after 10 days at 0.3, 1.1, and 3.3 \textmu M.

![Scheme 2. Synthesis of oxysterol 4.](image2)
Generally speaking, excessive polarity is not tolerated in the side-chain region (R1/R2) of the molecule, with the notable exception of some heterocyclic substitutions (compounds 25 and 26). Differences in activity can be discerned for substituted alkyl derivatives with a slight preference for the n-hexyl (compounds 21 and 30) when compared to the isohexyl (compound 4) and phenpropyl derivatives (compound 24). Next, we addressed the role of the C-21 methyl-group which is in close proximity to the C-20 hydroxyl group. Although, chain extension to the ethyl group was tolerated at C-21, the introduction of larger groups such as phenyl was not (compounds 27 and 28), whereas the C-20-R tertiary alcohol was inactive (compound 12). Compounds 27, 28 and 12 were prepared according to chemistry depicted in Scheme 3 starting with the corresponding substituted ketones, 10a–c (Scheme 3).

The latter were available from pregnenolone acetate, (5c), in 3 steps via a haloform reaction, Weinreb-amidation and Grignard addition, as shown in Scheme 3. The synthesis of the C-20-R tertiary alcohol 12 was accomplished via Grignard reaction of the ketone 10c, followed by hydroboration.


Stability data in human liver microsomes (HLM) obtained for some of the compounds listed in Table 1 indicates that metabolic stability is lacking for lead compound 4 and close analogues such as compound 21 (3% and 2% remaining after 1 h incubation). The

Scheme 4. Enzymatic degradation of oxysterols, for example, cholesterol.

Scheme 5. Synthesis of deuterated analogues.
increasing HLM stability exhibited with compounds 27 and 28 suggests that side-chain-substitution can affect metabolic stability, designating this region of the molecule as a possible site for cytochrome P450 (CYP)-metabolism. Among the multitude of CYP enzymes, CYP11A1,23 is known to specialize in the tissue specific conversion of cholesterol (13) to pregnenolone (5a), via a side-chain cleavage reaction illustrated in Scheme 4. The rate limiting step in this process is the formation of intermediate 14, 20(α), 22(R)-dihydroxycholesterol. The oxidation is believed to occur in a stepwise manner, first at C-22, then at C-20 followed by rapid cleavage of the glycol, releasing pregnenolone (5a) and isocaproic aldehyde.23 Given the structural analogy of intermediate 14 and the lead compound 4, we surmised that the presence of the 20(S)-hydroxyl group in 4 could lower the activation barrier toward similar metabolic degradation (via a putative intermediate analogous to 14), resulting in low HLM stability of 4. In this context, the synthesis of deuterated analogs of 4 was explored, given the ready access to various alkyne intermediates (Schemes 2 and 5). Remarkably, compound 18, the C-22, C-23-tetradeuterated analog of 4, displayed significantly increased HLM stability while retaining all potency in the Light2 and C3H10T1/2 assays (Table 1). Similar results were obtained for 30, the tetradeuterated version of 21 (Table 1). In order to examine the stabilizing kinetic isotope effect24 of the deuterium substitution in more detail, analogs of compound 4 were prepared in which deuterium atoms were introduced stepwise in a stereo-selective manner, as depicted in Scheme 5 with the synthesis of compounds 18, 19 and 20. Alkyne 15 was fully deuterated to afford 18, or subjected to a partial reduction with Lindlar’s catalyst using either hydrogen or deuterium gas. The partially reduced products 16 and 17 were then further reduced using hydrogen or deuterium gas in reverse order, to afford, after deprotection, 19 and 20.

The stereochemical outcome can be rationalized based on conformational preferences (‘inside alkoxyl effect’) of partially reduced products 16 and 17,25 which direct the second reduction, as suggested in Figure 1. In this way, the atom that is added to C-22 during the Lindlar reduction of the alkyne winds up on the re-face of the fully reduced molecule and determines the HLM stability of the product: hydrogen, in the case of 19, and, deuterium, in the case of 20. As depicted in Table 2, compounds 4, 18, 19 and 20 performed similarly in the Light2 assay, but displayed significant differences in the rates of intrinsic clearance in HLM. The increased stability of compounds 18 and 20 relative to compounds 4 and 19 supports the notion that a stereoselective C–H bond cleavage at C-22 could be involved during a rate limiting step of HLM clearance.

While HLM stability measurements are meant to model hepatic clearance, very little can be inferred from this data regarding metabolism in the local bone environment. Cholesterol and steroid metabolism is prominently associated with non-bone tissues (e.g., liver, adrenal gland); however, osteoblasts are known for their metabolism in the local bone environment. Conceivably, deuterated oxysterol analogues such as compound 18 and 30 may attenuate this process, potentially resulting in improved in vivo performance. In order to correlate in vitro properties such as potency and metabolic stability with in vivo efficacy, compounds 4, 18, and 21 were selected further study. Compared to lead compound 4, deuterated analogue 18 displays greater HLM stability, whereas compound 21 is more potent inducer of osteocalcin production (Table 1).

The in vivo effects of compounds 4, 18, and 21 were evaluated locally in a spinal fusion model in rats.29 Each compound was dissolved in DMSO to a concentration of 50 mg/mL, and 40 μL of the dissolved compound was added to a collagen sponge. The compound/sponge was incubated at room temperature for 1–2 h before implantation. Sprague Dawley rats were implanted bilaterally between the L4 and L5 segments after decorticating transverse processes at these segments. Decorticating provides bone marrow MSCs in the fusion site. Eight weeks after implantation, the

Table 2

Deuteration of the side-chain and HLM stability

<table>
<thead>
<tr>
<th>Compd</th>
<th>R</th>
<th>Hh light 2 EC50 (μM)</th>
<th>Intrinsic clearance in HLM t1/2 (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td></td>
<td>0.8</td>
<td>4*</td>
</tr>
<tr>
<td>18</td>
<td></td>
<td>1.2</td>
<td>&gt;120*</td>
</tr>
<tr>
<td>19</td>
<td></td>
<td>1.1</td>
<td>5*</td>
</tr>
<tr>
<td>20</td>
<td></td>
<td>1.0</td>
<td>&gt;120*</td>
</tr>
</tbody>
</table>

* Measured after 0, 15, 30, 45 and 60 min.

Figure 1. Inside-alkoxy effect for addition to steroidal alkenes.

Figure 2. Mechanical stability of treated lumbar vertebral segments assessed by manual palpation. The positive control, 4, and the test compounds, 21 and 18, all induced partial vertebral fusion (mean ± SD, n = 10/treatment group).
will report additional data on compounds metabolic activation involving the side-chain at C-22 and C-23. We compared to parent compound analogues. Dosed at 4 mg/kg in a rat spinal fusion model, deuterated analogue did not produce a significantly enhanced response to this positive control. As shown in Figure 2, mechanical stability testing of treated vertebral segment did not reveal a difference between 21 or 18 and 4. A trend towards higher scores for the 21 and 18 groups compared to 4 was noted, but did not reach statistical significance when analyzed by Kruskal-Wallis testing, a nonparametric analysis of variance. MicroCT analysis revealed a larger bone volume in the callus of 21-treated rats compared to 4, while 18 treated animals were comparable to 4-treated rats (Figure 3).

In conclusion, a tentative correlation of in vitro potency (Hh-activity and OCN induction, Table 1) and a single in vivo efficacy outcome (Bone Volume, Figure 3) was observed with oxysterol analogues 4 and 21, affirming the importance of potency optimization. Dosed at 4 mg/kg in a rat spinal fusion model, deuterated analogue 18 did not produce a significantly enhanced response compared to parent compound 4, suggesting that in vivo efficacy may not be exclusively limited by metabolic stability. These results also suggest that in vivo efficacy of 4 may not be a consequence of metabolic activation involving the side-chain at C-22 and C-23. We will report additional data on compounds 21 and 30 in due time.

Acknowledgment

We wish to thank Dr. Eugene Thorsett for his wisdom and guidance through this work.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.bmcl.2012.07.073.

References and notes

18. SHHlight2 assay: Activation of the Hedgehog pathway was measured using the SHHlight2 reporter cell line. This reporter line contains a concatemer of 8 Gli response elements upstream of a minimal promoter driving the expression of firefly luciferase. The cells constitutively express Renilla luciferase for normalization of the firefly luciferase signal. SHHlight2 cells were plated at 10,000 cells/well in 384 well plates with 20 μl/well of DMEM/10% FCS. 24 h after plating, cells were treated 20 μl/well of test compound in DMEM/0.5% FCS. Triplicate wells were used for each treatment. After 24 h of treatment, firefly luciferase and Renilla luciferase were measured with Promega’s DualGlo reagent. The firefly signal in each well was divided by the Renilla signal in that well to normalize for cell number, and results are expressed relative to cells treated with the DMSO solvent control.

C3H/10T1/2 Osteogenesis assay: The ability of test compounds to stimulate osteogenesis was measured in vitro using the C3H/10T1/2 cell line. This multipotential cell line is a model of mesenchymal stem cells, and can be differentiated into osteoblasts, chondrocytes, myoblasts and adipocytes. C3H/10T1/2 cells were plated in 24 well plates and cultured to confluence in DMEM/10% FCS. After reaching confluence, duplicate wells of cells were treated 3 times per week for 2 weeks with test compound in fresh DMEM/10% FCS. Total RNA was prepared using the Qiagen RNeasy Plus kit, and cDNA was created from total RNA using invertigo superscript III kit. Quantitative RT-PCR was performed on cDNA samples using ABI Taqman assays, with the ΔΔCt method, to measure the expression levels of osteoblast genes, RCLAP and IBSP. Results were normalized to GAPDH and expressed relative to cells treated with the DMSO solvent control: Dworetzky, S. I.; Fey, G. C.; Pennman, S.; Lian, J. B.; Stein, J. L.; Stein, G. S. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 4605.

22. HLM stability and intrinsic clearance data were obtained by Cerep, Bothell, WA.

28. Testing in the rat spinal fusion model was performed by Ricerca, Bothell, WA.